Publication: Biological treatment may be an option as first steroid-sparing agent in a subgroup of young Takayasu Arteritis patients with prominent acute phase reactants and constitutional symptoms
Program
KU-Authors
Kanıtez, Nilüfer Alpay
KU Authors
Co-Authors
Kaymaz-Tahra, Sema
Tsechelidis, Ozun Bayindir
Ince, Burak
Ozdemir-Isik, Ozlem
Kutu, Muhammet Emin
Karakas, Ozlem
Demirci-Yildirim, Tuba
Ademoglu, Zeliha
Ediboglu, Elif
Uludogan, Burcu Ceren
Advisor
Publication Date
Language
Type
Journal Title
Journal ISSN
Volume Title
Abstract
Background/Purpose: There is no data on which patients biologic immunosuppressive (bIS) treatment should be chosen in Takayasu’s arteritis (TAK). In this study we aimed to assess the characteristics of TAK patients needed biologic treatment during follow-up in daily practice.
Source:
ARTHRITIS and RHEUMATOLOGY
Publisher:
Wiley
Keywords:
Subject
Rheumatology